Dolutegravir

J - Antiinfectives For Systemic Use -> J05 - Antivirals For Systemic Use -> J05A - Direct Acting Antivirals -> J05AX - Other Antivirals -> J05AX12 - Dolutegravir
Administration category: Free Medicine group: antiviral Brand name: Tivicay

Safety margins

≥ 18 years
WeightROADosage
≥ 40 kg
ROA:
po
Dosage:
min. 50mg 1 dd to max. 50mg 2 dd

Standard dosages

≥ 18 years
WeightROALoadDosage
ROA:
po
Load:
-
Dosage:
50mg 1 dd
Comments:

Bij resistentie voor integraseremmer en bij combinatie met efavirenz, nevirapine, tipranavir geboost met ritonavir, of rifampicine: 50 mg 2 dd

≥ 40 kg
ROA:
po
Load:
-
Dosage:
50mg 1 dd
Comments:

Bij resistentie voor integraseremmer en bij combinatie met efavirenz, nevirapine, tipranavir geboost met ritonavir, of rifampicine: 50 mg 2 dd

Kidney function

Renal elimination: 32%
Dosage: independent on kidney function

Renal function-replacement therapy

CAPD: geen gegevens bekend

Hemo dialysis: geen gegevens bekend

Interactions

Interaction with (ATC): Expected effect:
Interaction with (ATC):
J05AG03 - Efavirenz
Expected effect:
dolutegravir 2 dd 50 mg
Interaction with (ATC):
J05AG01 - Nevirapine
Expected effect:
dolutegravir 2 dd 50 mg
Interaction with (ATC):
J05AE09 - Tipranavir
Expected effect:
dolutegravir 2 dd 50 mg
Interaction with (ATC):
J04AB02 - Rifampicin
Expected effect:
dolutegravir 2 dd 50 mg

Pregnancy

Due to the expiration of the alphanumeric classification for use in pregnancy and lactation, reference is made to the current, online information of the Teratology Information Service (TIS) of LAREB:

For individual advice, consult an expert on site.
Metadata

Swab vid: M-287573.1
Updated: 06/16/2019 - 20:05
Status: Published

External links
Menu position